GELSOMINO, FRANCESCO
GELSOMINO, FRANCESCO
A case series of non-small cell lung cancer patients with EGFR or HER2 exon 20 insertion in Li Fraumeni syndrome
2024 Cognigni V.; Capelletto E.; Bordi P.; Pavese V.; Carfi F.M.; Gelsomino F.; De Giglio A.; Chiari R.; Minari R.; Ambrosini E.; Percesepe A.; Giachino D.; Bironzo P.; Tiseo M.
A new classification of upper gastrointestinal toxicity induced by immunotherapy: from endoscopic and pathological insights to clinical management
2024 Casadio, C.; Galvani, L.; De Giglio, A.; Casadei, C.; Tardio, M.L.; Melotti, B.; Sperandi, F.; Gelsomino, F.; Comito, F.
Ad(aura): a fresh breeze for patients with resected EGFR-mutant non-small cell lung cancer
2024 Conci N.; De Giglio A.; Sperandi F.; Melotti B.; Gelsomino F.
Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations
2024 Di Federico, Alessandro; Angelicola, Stefania; Frascino, Mariateresa; Siracusa, Irene; Bisanti, Beatrice; Ruzzi, Francesca; Semprini, Maria Sofia; De Jonge, Hugo; De Giglio, Andrea; Sperandi, Francesca; Brocchi, Stefano; Melotti, Barbara; Giunchi, Francesca; Gruppioni, Elisa; Altimari, Annalisa; Lollini, Pier-Luigi; Ardizzoni, Andrea; Palladini, Arianna; Gelsomino, Francesco
Early monitoring of plasma KRAS G12C with digital PCR predicts antitumor response to immunotherapy or sotorasib in advanced NSCLC: A brief report
2024 De Giglio, Andrea; Zacchini, Federico; Venturi, Giulia; Di Federico, Alessandro; Parisi, Claudia; Dall'Olio, Filippo Gustavo; Ricciotti, Ilaria; Favorito, Valentina; Gagliano, Ambrogio; De Biase, Dario; Maloberti, Thais; Altimari, Annalisa; Gruppioni, Elisa; Tallini, Giovanni; Melotti, Barbara; Sperandi, Francesca; Gelsomino, Francesco; Montanaro, Lorenzo; Ardizzoni, Andrea
Effective retreatment with osimertinib in CNS-relapsed epidermal growth factor receptor-mutant non-small cell lung cancer patient following resection and adjuvant osimertinib
2024 Di Federico A.; De Giglio A.; Sperandi F.; Melotti B.; Ardizzoni A.; Gelsomino F.
From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC)
2024 Fabbri L.; Di Federico A.; Astore M.; Marchiori V.; Rejtano A.; Seminerio R.; Gelsomino F.; De Giglio A.
Histopathological Evidence for a Non-Inflammatory Mechanism in Osimertinib-Induced Myopathy: A Case Report
2024 Rossi S.; Costa R.; di Federico A.; Lo Bianco F.; D'Angelo R.; Asioli G.M.; De Giglio A.; Sperandi F.; Guarino M.; Rinaldi R.; Ardizzoni A.; Cenacchi G.; Gelsomino F.
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed
2024 Leonetti, A.; Perrone, F.; Puntoni, M.; Maglietta, G.; Bordi, P.; Bria, E.; Vita, E.; Gelsomino, F.; De Giglio, A.; Gelibter, A.; Siringo, M.; Mazzoni, F.; Caliman, E.; Genova, C.; Bertolini, F.; Guaitoli, G.; Passiglia, F.; Delcuratolo, M. D.; Montrone, M.; Cerea, G.; Pasello, G.; Roca, E.; Belluomini, L.; Cecere, F. L.; Guida, A.; Manzo, A.; Adamo, V.; Rastelli, F.; Bulotta, A.; Citarella, F.; Toschi, L.; Zoratto, F.; Cortinovis, D. L.; Berardi, R.; Follador, A.; Carta, A.; Camerini, A.; Salerno, F.; Silva, R. R.; Baldini, E.; Cortellini, A.; Brighenti, M.; Santoni, M.; Malorgio, F.; Caminiti, C.; Tiseo, M.
Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary
2024 Cavazzoni A.; Salamon I.; Fumarola C.; Gallerani G.; Laprovitera N.; Gelsomino F.; Riefolo M.; Rihawi K.; Porcellini E.; Rossi T.; Mazzeschi M.; Naddeo M.; Serravalle S.; Broseghini E.; Agostinis F.; Deas O.; Roncarati R.; Durante G.; Pace I.; Lauriola M.; Garajova I.; Calin G.A.; Bonafe M.; D'Errico A.; Petronini P.G.; Cairo S.; Ardizzoni A.; Sales G.; Ferracin M.
Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors
2023 Sisi, Monia; Vitale, Giovanni; Fusaroli, Michele; Riefolo, Mattia; Giunchi, Valentina; D’Errico, Antonietta; Ardizzoni, Andrea; Raschi, Emanuel; Gelsomino, Francesco
First-Generation Epidermal Growth Factor Receptor Inhibitors Plus Antiangiogenic Drugs Versus Third-Generation Epidermal Growth Factor Receptor Inhibitors in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis
2023 Mosca, Mirta; Conci, Nicole; Di Federico, Alessandro; Tateo, Valentina; Favorito, Valentina; Zappi, Arianna; Gelsomino, Francesco; De Giglio, Andrea
Neurological Manifestations as a Harbinger of Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
2023 Rossi, Simone; Cani, Ilaria; Raschi, Emanuel; Comito, Francesca; Rinaldi, Rita; Ardizzoni, Andrea; Guarino, Maria; Gelsomino, Francesco
Predictors of Survival to Immunotherapy and Chemoimmunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis
2023 Di Federico, Alessandro; De Giglio, Andrea; Gelsomino, Francesco; Sperandi, Francesca; Melotti, Barbara; Ardizzoni, Andrea
Relatlimab and nivolumab in untreated advanced melanoma: insight into RELATIVITY
2023 Raschi E.; Comito F.; Massari F.; Gelsomino F.
A phase II, open-label, single arm, trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale
2022 Andrini, Elisa; Lamberti, Giuseppe; Mazzoni, Francesca; Riccardi, Ferdinando; Bonetti, Andrea; Follador, Alessandro; Artioli, Fabrizio; Genova, Carlo; Barbieri, Fausto; Frassoldati, Antonio; Brighenti, Matteo; Colantonio, Ida; Pasello, Giulia; Ficorella, Corrado; Cinieri, Saverio; Tiseo, Marcello; Gelsomino, Francesco; Tognetto, Michele; Rihawi, Karim; Ardizzoni, Andrea
ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1- rearranged NSCLC
2022 Ruzzi, Francesca; Angelicola, Stefania; Landuzzi, Lorena; Nironi, Elena; Semprini, Maria Sofia; Scalambra, Laura; Altimari, Annalisa; Gruppioni, Elisa; Fiorentino, Michelangelo; Giunchi, Francesca; Ferracin, Manuela; Astolfi, Annalisa; Indio, Valentina; Ardizzoni, Andrea; Gelsomino, Francesco; Nanni, Patrizia; Lollini, Pier-Luigi; Palladini, Arianna
Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes
2022 Di Federico, Alessandro; De Giglio, Andrea; Gelsomino, Francesco; De Biase, Dario; Giunchi, Francesca; Palladini, Arianna; Sperandi, Francesca; Melotti, Barbara; Ardizzoni, Andrea
Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC)
2022 De Giglio, Andrea; Aprile, Marta; Di Federico, Alessandro; Sperandi, Francesca; Melotti, Barbara; Gelsomino, Francesco; Ardizzoni, Andrea
Monitoring tumor growth rate to predict immune checkpoint inhibitors' treatment outcome in advanced NSCLC
2022 Dall'Olio, Filippo G; Parisi, Claudia; Marcolin, Laura; Brocchi, Stefano; Caramella, Caroline; Conci, Nicole; Carpani, Giulia; Gelsomino, Francesco; Ardizzoni, Stefano; Marchese, Paola Valeria; Paccapelo, Alexandro; Grilli, Giada; Golfieri, Rita; Besse, Benjamin; Ardizzoni, Andrea
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| A case series of non-small cell lung cancer patients with EGFR or HER2 exon 20 insertion in Li Fraumeni syndrome | Cognigni V.; Capelletto E.; Bordi P.; Pavese V.; Carfi F.M.; Gelsomino F.; De Giglio A.; Chiari R....; Minari R.; Ambrosini E.; Percesepe A.; Giachino D.; Bironzo P.; Tiseo M. | 2024-01-01 | TUMORI | - | 1.01 Articolo in rivista | - |
| A new classification of upper gastrointestinal toxicity induced by immunotherapy: from endoscopic and pathological insights to clinical management | Casadio, C.; Galvani, L.; De Giglio, A.; Casadei, C.; Tardio, M.L.; Melotti, B.; Sperandi, F.; Ge...lsomino, F.; Comito, F. | 2024-01-01 | ESMO GASTROINTESTINAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Ad(aura): a fresh breeze for patients with resected EGFR-mutant non-small cell lung cancer | Conci N.; De Giglio A.; Sperandi F.; Melotti B.; Gelsomino F. | 2024-01-01 | CHINESE CLINICAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations | Di Federico, Alessandro; Angelicola, Stefania; Frascino, Mariateresa; Siracusa, Irene; Bisanti, B...eatrice; Ruzzi, Francesca; Semprini, Maria Sofia; De Jonge, Hugo; De Giglio, Andrea; Sperandi, Francesca; Brocchi, Stefano; Melotti, Barbara; Giunchi, Francesca; Gruppioni, Elisa; Altimari, Annalisa; Lollini, Pier-Luigi; Ardizzoni, Andrea; Palladini, Arianna; Gelsomino, Francesco | 2024-01-01 | JCO PRECISION ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Early monitoring of plasma KRAS G12C with digital PCR predicts antitumor response to immunotherapy or sotorasib in advanced NSCLC: A brief report | De Giglio, Andrea; Zacchini, Federico; Venturi, Giulia; Di Federico, Alessandro; Parisi, Claudia;... Dall'Olio, Filippo Gustavo; Ricciotti, Ilaria; Favorito, Valentina; Gagliano, Ambrogio; De Biase, Dario; Maloberti, Thais; Altimari, Annalisa; Gruppioni, Elisa; Tallini, Giovanni; Melotti, Barbara; Sperandi, Francesca; Gelsomino, Francesco; Montanaro, Lorenzo; Ardizzoni, Andrea | 2024-01-01 | THE JOURNAL OF LIQUID BIOPSY | - | 1.01 Articolo in rivista | - |
| Effective retreatment with osimertinib in CNS-relapsed epidermal growth factor receptor-mutant non-small cell lung cancer patient following resection and adjuvant osimertinib | Di Federico A.; De Giglio A.; Sperandi F.; Melotti B.; Ardizzoni A.; Gelsomino F. | 2024-01-01 | ANTI-CANCER DRUGS | - | 1.01 Articolo in rivista | - |
| From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC) | Fabbri L.; Di Federico A.; Astore M.; Marchiori V.; Rejtano A.; Seminerio R.; Gelsomino F.; De Gi...glio A. | 2024-01-01 | DIAGNOSTICS | - | 1.01 Articolo in rivista | diagnostics-14-00048-v2.pdf |
| Histopathological Evidence for a Non-Inflammatory Mechanism in Osimertinib-Induced Myopathy: A Case Report | Rossi S.; Costa R.; di Federico A.; Lo Bianco F.; D'Angelo R.; Asioli G.M.; De Giglio A.; Sperand...i F.; Guarino M.; Rinaldi R.; Ardizzoni A.; Cenacchi G.; Gelsomino F. | 2024-01-01 | JOURNAL OF THORACIC ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed | Leonetti, A.; Perrone, F.; Puntoni, M.; Maglietta, G.; Bordi, P.; Bria, E.; Vita, E.; Gelsomino, ...F.; De Giglio, A.; Gelibter, A.; Siringo, M.; Mazzoni, F.; Caliman, E.; Genova, C.; Bertolini, F.; Guaitoli, G.; Passiglia, F.; Delcuratolo, M. D.; Montrone, M.; Cerea, G.; Pasello, G.; Roca, E.; Belluomini, L.; Cecere, F. L.; Guida, A.; Manzo, A.; Adamo, V.; Rastelli, F.; Bulotta, A.; Citarella, F.; Toschi, L.; Zoratto, F.; Cortinovis, D. L.; Berardi, R.; Follador, A.; Carta, A.; Camerini, A.; Salerno, F.; Silva, R. R.; Baldini, E.; Cortellini, A.; Brighenti, M.; Santoni, M.; Malorgio, F.; Caminiti, C.; Tiseo, M. | 2024-01-01 | EUROPEAN JOURNAL OF CANCER | - | 1.01 Articolo in rivista | - |
| Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary | Cavazzoni A.; Salamon I.; Fumarola C.; Gallerani G.; Laprovitera N.; Gelsomino F.; Riefolo M.; Ri...hawi K.; Porcellini E.; Rossi T.; Mazzeschi M.; Naddeo M.; Serravalle S.; Broseghini E.; Agostinis F.; Deas O.; Roncarati R.; Durante G.; Pace I.; Lauriola M.; Garajova I.; Calin G.A.; Bonafe M.; D'Errico A.; Petronini P.G.; Cairo S.; Ardizzoni A.; Sales G.; Ferracin M. | 2024-01-01 | MOLECULAR THERAPY | - | 1.01 Articolo in rivista | 2024_MolTher_CUP-models.pdf; ScienceDirect_files_14-10-27.154.zip |
| Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors | Sisi, Monia; Vitale, Giovanni; Fusaroli, Michele; Riefolo, Mattia; Giunchi, Valentina; D’Errico, ...Antonietta; Ardizzoni, Andrea; Raschi, Emanuel; Gelsomino, Francesco | 2023-01-01 | JTO CLINICAL AND RESEARCH REPORTS | - | 1.01 Articolo in rivista | Sisi et al. JTO CCR 23.pdf; Sisi et al. JTO CCR supplementary 23.pdf |
| First-Generation Epidermal Growth Factor Receptor Inhibitors Plus Antiangiogenic Drugs Versus Third-Generation Epidermal Growth Factor Receptor Inhibitors in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis | Mosca, Mirta; Conci, Nicole; Di Federico, Alessandro; Tateo, Valentina; Favorito, Valentina; Zapp...i, Arianna; Gelsomino, Francesco; De Giglio, Andrea | 2023-01-01 | JCO PRECISION ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Neurological Manifestations as a Harbinger of Myocarditis in Patients Treated With Immune Checkpoint Inhibitors | Rossi, Simone; Cani, Ilaria; Raschi, Emanuel; Comito, Francesca; Rinaldi, Rita; Ardizzoni, Andrea...; Guarino, Maria; Gelsomino, Francesco | 2023-01-01 | JOURNAL OF CLINICAL ONCOLOGY | - | 1.04 Replica / breve intervento (e simili) | - |
| Predictors of Survival to Immunotherapy and Chemoimmunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis | Di Federico, Alessandro; De Giglio, Andrea; Gelsomino, Francesco; Sperandi, Francesca; Melotti, B...arbara; Ardizzoni, Andrea | 2023-01-01 | JOURNAL OF THE NATIONAL CANCER INSTITUTE | - | 1.01 Articolo in rivista | - |
| Relatlimab and nivolumab in untreated advanced melanoma: insight into RELATIVITY | Raschi E.; Comito F.; Massari F.; Gelsomino F. | 2023-01-01 | IMMUNOTHERAPY | - | 1.01 Articolo in rivista | - |
| A phase II, open-label, single arm, trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale | Andrini, Elisa; Lamberti, Giuseppe; Mazzoni, Francesca; Riccardi, Ferdinando; Bonetti, Andrea; Fo...llador, Alessandro; Artioli, Fabrizio; Genova, Carlo; Barbieri, Fausto; Frassoldati, Antonio; Brighenti, Matteo; Colantonio, Ida; Pasello, Giulia; Ficorella, Corrado; Cinieri, Saverio; Tiseo, Marcello; Gelsomino, Francesco; Tognetto, Michele; Rihawi, Karim; Ardizzoni, Andrea | 2022-01-01 | FUTURE ONCOLOGY | - | 1.01 Articolo in rivista | - |
| ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1- rearranged NSCLC | Ruzzi, Francesca; Angelicola, Stefania; Landuzzi, Lorena; Nironi, Elena; Semprini, Maria Sofia; S...calambra, Laura; Altimari, Annalisa; Gruppioni, Elisa; Fiorentino, Michelangelo; Giunchi, Francesca; Ferracin, Manuela; Astolfi, Annalisa; Indio, Valentina; Ardizzoni, Andrea; Gelsomino, Francesco; Nanni, Patrizia; Lollini, Pier-Luigi; Palladini, Arianna | 2022-01-01 | TRANSLATIONAL LUNG CANCER RESEARCH | - | 1.01 Articolo in rivista | ADK-VR2 TLCR.pdf; tlcr-11-11-2216-coif.zip |
| Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes | Di Federico, Alessandro; De Giglio, Andrea; Gelsomino, Francesco; De Biase, Dario; Giunchi, Franc...esca; Palladini, Arianna; Sperandi, Francesca; Melotti, Barbara; Ardizzoni, Andrea | 2022-01-01 | CANCERS | - | 1.01 Articolo in rivista | cancers-14-03472-v2.pdf; cancers-14-03472-s001.zip |
| Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC) | De Giglio, Andrea; Aprile, Marta; Di Federico, Alessandro; Sperandi, Francesca; Melotti, Barbara;... Gelsomino, Francesco; Ardizzoni, Andrea | 2022-01-01 | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | - | 1.01 Articolo in rivista | ijms-23-10292.pdf |
| Monitoring tumor growth rate to predict immune checkpoint inhibitors' treatment outcome in advanced NSCLC | Dall'Olio, Filippo G; Parisi, Claudia; Marcolin, Laura; Brocchi, Stefano; Caramella, Caroline; Co...nci, Nicole; Carpani, Giulia; Gelsomino, Francesco; Ardizzoni, Stefano; Marchese, Paola Valeria; Paccapelo, Alexandro; Grilli, Giada; Golfieri, Rita; Besse, Benjamin; Ardizzoni, Andrea | 2022-01-01 | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | - | 1.01 Articolo in rivista | 12. Dall'Olio_Monitoring Tumor Growth Rate to predict Immune Checkpoint Inhibitors’ treatment outcome in advanced NSCLC.pdf |